NCT06817720 2026-04-16
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
8 trialsNCT07178912 2026-03-09
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT04126681 2025-03-03
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
Phase 2 Completed
NCT06754267 2024-12-31
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06220487 2024-01-24
ABC
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT03883087 2023-04-03
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation
Ascentage Pharma Group Inc.
Phase 2 Unknown
NCT03883100 2023-04-03
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
Ascentage Pharma Group Inc.
Phase 2 Unknown
NCT05521204 2022-08-30
Olverembatinib for FGFR1-rearranged Neoplasms
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting